HCPLive

Cadaveric Growth Hormone Does Not Appear to Transmit Alzheimer’s, Parkinson’s Disease

 
cadaveric growth hormone does not transmit Alzheimer's disease or Parkinson's diseaseTUESDAY, Feb. 5 (HealthDay News) -- There seems to be no evidence to support human-to-human transmission of Alzheimer's disease (AD) or Parkinson's disease (PD) via transmission of neurodegenerative disease (ND)-associated proteins (NDAPs) in recipients of cadaveric human growth hormone (c-hGH), according to a study published online Feb. 4 in JAMA Neurology.

Noting the growing evidence of cell-to-cell transmission of NDAPs, David J. Irwin, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined evidence for human-to-human transmission of AD, PD, and related NDAPs in 34 routine autopsy subjects (10 non-ND controls and 24 patients with ND) and among recipients of c-hGH in the U.S. National Hormone and Pituitary Program (NHPP) cohort.

In ND and control patients, the researchers identified mild amounts of pathological tau, amyloid-β, and α-synuclein deposits in the adeno/neurohypophysis. Among U.S. NHPP c-hGH recipients, there were no cases of AD or PD; three deaths were attributed to amyotrophic lateral sclerosis.

"In this unique in vivo model of human-to-human transmission, we found no evidence to support concerns that NDAPs underlying AD and PD transmit disease in humans despite evidence of their cell-to-cell transmission in model systems of these disorders," the authors write. "Further monitoring is required to confirm these conclusions."

Two authors disclosed financial ties to the pharmaceutical industry.
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

A recent study looked into the neural functions affected by ibuprofen and found some connections that may soon lead to a much greater understanding of the greatest pain mitigator of them all: the brain.
Discontinuation of multiple sclerosis medication saw nearly 2 in 5 patients experience some form of increased disease activity, according to research from NYU Langone Medical Center.
As more research is done the more it appears brown fat will play a key role in the future treatment of diabetes.
Weighing the pros and cons of prescription opioid use for chronic pain is an ongoing battle, and new research may have just added to the list of disadvantages.
$vAR$